TCHP and cancer: In summary, the dysregulation of proteins involved in Ca2+ transport at MAMs or in oncogenes and tumor suppressor proteins in cancer, alters Ca2+ transfer from the ER to the mitochondria, and, whether the outcome is the inhibition of Ca2+ transfer or Ca2+ overload, it will contribute directly to cancer disease progression by modulating cell death and/or survival.